Why Your Pre-Bed HGH Injection Is Built For The Wrong Body

Your liver does not care how much growth hormone is in your blood. It cares whether the conditions are right to do something with it.

That distinction is the whole reason timing matters, and it is the reason a protocol designed for one type of body gets copied and used by a completely different one.

Start with the big picture. Growth hormone does not build tissue directly. It travels from wherever it is produced or injected to your liver, and your liver converts it into something called IGF-1, which stands for insulin-like growth factor 1, and IGF-1 is the molecule that actually signals muscle cells to grow, recover, and take up nutrients. Growth hormone is the order. IGF-1 is the delivery. Without conversion, the order sits in the system and does nothing useful, and more than that, it starts causing problems.

So the question is never just "how much growth hormone do I have in my blood?" The question is "is my liver in a state where it will convert that growth hormone into IGF-1?"

That conversion depends on insulin.

When insulin is present and your liver is receptive, growth hormone gets converted efficiently. When insulin is absent, or when growth hormone has been elevated long enough that your liver has started resisting its signal, the conversion rate drops and you are left with circulating growth hormone that is doing the opposite of what you wanted, pushing back against insulin, raising fasting glucose, and blunting the body's own hormonal output.

Now look at what your body is already doing on its own.

Research by Van Cauter and Plat published in 1996 documented that the largest pulse of endogenous growth hormone, meaning the pulse your pituitary produces without any external input, happens during slow-wave sleep, typically one to two hours after you fall asleep. This single pulse accounts for roughly 70 percent of your total daily growth hormone output. Your body is running a timed release of its most anabolic signal every single night for free.

This matters because growth hormone is what is called counter-regulatory, which means it works against insulin rather than with it. At the liver specifically, elevated growth hormone reduces insulin sensitivity and tells the liver to hold onto glucose rather than allow it to be cleared. This is the same mechanism behind something called the dawn phenomenon, where people wake up with elevated fasting glucose not because they ate anything overnight, but because the nocturnal growth hormone pulse suppressed hepatic insulin sensitivity for hours. Perriello and colleagues showed in 1990 that the nocturnal spikes of growth hormone were sufficient to decrease hepatic insulin sensitivity entirely in the absence of any other variable, and that this effect persisted through the early morning hours.

So when someone injects exogenous growth hormone subcutaneously at ten o'clock at night, what happens?

The pharmacokinetics from Jorgensen and colleagues show that a subcutaneous injection peaks in the bloodstream roughly four hours after administration. A ten PM injection peaks around two in the morning, which lands directly on top of the body's own endogenous growth hormone pulse. You have now doubled the counter-regulatory signal at exactly the moment your liver is already in a low-insulin, insulin-resistant state. You get suppressed insulin sensitivity through the night, elevated fasting glucose in the morning, and a groggy, foggy wakeup that reflects glucose dysregulation rather than rest.

And here is the other cost. Elevated exogenous growth hormone competes with and suppresses the feedback signals that drive your pituitary's own pulse. You are blunting the pulse your body is producing for free and replacing it with a synthetic peak that misses the conversion window entirely, because at two in the morning there is no meal insulin coming to pair with it and complete the conversion sequence.

Now look at where the pre-bed timing protocol actually came from.

The 1990 study by Jorgensen and colleagues compared evening versus morning injections of growth hormone in GH-deficient patients. These were people whose pituitary glands had stopped functioning. They had no endogenous pulse at all, meaning there was no natural signal to suppress, no nocturnal peak to stack on top of, no feedback loop to disrupt. The study found that 24-hour IGF-1 levels came out essentially equivalent regardless of whether patients injected in the morning or the evening. Neither timing produced a meaningful advantage.

That finding was not a verdict that evening injections were optimal. It was a finding that in a body with no natural pulse, timing made no detectable difference. The study was never designed for and never claimed applicability to someone with an intact, functioning pituitary.

The protocol migrated from a clinical paper about a specific patient population into general use without carrying that context along with it.

For someone whose pituitary is still firing every night, the calculus is completely different. The goal is not to avoid disrupting a pulse that does not exist. The goal is to work around a pulse that is already happening, and to hit the one window during the day where the liver is primed for conversion.

That window is the fasted morning state.

When you wake up after sleep, cortisol and growth hormone have both been elevated overnight, your liver has been in a glucose-producing state, and insulin is low. If you inject growth hormone in a fasted state first thing in the morning, the injected growth hormone begins rising in your blood and reaches peak concentration roughly three to four hours later. If you eat your first meal thirty to sixty minutes after the injection, insulin from that meal arrives while growth hormone is climbing toward peak. Your liver is now receiving both signals at the same time, and that is the condition under which hepatic IGF-1 conversion runs efficiently. You are pairing the order with the delivery mechanism rather than sending the order at two in the morning when the delivery system is already occupied with something else.

At doses of four international units or higher, the standard approach is to split the daily dose between morning and mid-to-late afternoon rather than taking it all at once. A morning injection covers the post-breakfast and midday window. An afternoon injection, timed the same way relative to a meal, covers the late afternoon and early evening window. Both doses are timed to land during periods of rising or present insulin, and both are kept far enough from sleep that they are not contributing to the overnight counter-regulatory environment.

The body is running a system that already knows what it is doing at night. The smartest thing an exogenous protocol can do is stay out of its way during that window and use the hours when the body's own system is quiet to do the work the body cannot do for itself.

---

References

1. Van Cauter E, Plat L. (1996). Physiology of growth hormone secretion during sleep. J Pediatr 128(5 Pt 2):S32-37. DOI: 10.1016/s0022-3476(96)70008-2
2. Jorgensen JO, Moller N, Moller J, Weeke J, Christiansen JS. (1985). Pharmacokinetics of biosynthetic authentic human growth hormone in normal men after subcutaneous or intramuscular injection. Acta Endocrinol (Copenh). PMID: 4034296
3. Jorgensen JO, Moller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS. (1990). Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 70(1):207-14. PMID: 2294131. DOI: 10.1210/jcem-70-1-207
4. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. PMID: 19240267. DOI: 10.1210/er.2008-0027
5. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. (1990). Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33(1):52-9. PMID: 2406181. DOI: 10.1007/BF00586461

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness